EP0494225A1 - Lignees cellulaires epitheliales et oesophagiennes humaines - Google Patents

Lignees cellulaires epitheliales et oesophagiennes humaines

Info

Publication number
EP0494225A1
EP0494225A1 EP90914817A EP90914817A EP0494225A1 EP 0494225 A1 EP0494225 A1 EP 0494225A1 EP 90914817 A EP90914817 A EP 90914817A EP 90914817 A EP90914817 A EP 90914817A EP 0494225 A1 EP0494225 A1 EP 0494225A1
Authority
EP
European Patent Office
Prior art keywords
cells
cell line
het
esophageal
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP90914817A
Other languages
German (de)
English (en)
Other versions
EP0494225A4 (en
Inventor
Gary David Stoner
Roger Robert Reddel
Curtis Craig Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
US Department of Commerce
Original Assignee
US Department of Health and Human Services
US Department of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, US Department of Commerce filed Critical US Department of Health and Human Services
Publication of EP0494225A1 publication Critical patent/EP0494225A1/fr
Publication of EP0494225A4 publication Critical patent/EP0494225A4/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity

Definitions

  • the present invention relates to human epithelial cells that originate from the esophagus and are immortal- ized in culture, particularly to such cells genetically transformed with genes from tumor viruses, especially,
  • the present invention also relates to methods of using such cells for detection of various types of agents, for instance, chemicals that can cause cancer.
  • esophageal cancer is associated with exposure to chemical carcinogens in the environment and in the diet.
  • Factors associated with an increased risk of developing esophageal cancer include tobacco, alcoholic beverages, and moldy foods, all of which contain nitrosamines; and asbestos.
  • esophageal neoplasms probably are the result of a sequence of genetic and phenotypic changes in the esophageal epithelium.
  • the phenotypic keratin patterns of squamous cell carcinomas of the esophagus are consistently different from those of the normal tissue (S.P. Banks- Schlegal and C.C. Harris, Cancer Res. 1984, 44: 1153- 1157.) (M.P. Grace, K.H. Kim, L.D. True and Fuhs, 1985, Cancer Res. 45: 841-846).
  • the esophageal epithelial cell is able to form crosslinked envelopes when it terminally differentiates (S.P. Banks- Shlegal and C.C. Harris, Cancer Res. 1986, 250-258. This function is variably expressed in esophageal carcinomas (S.P.
  • N- nitrosobenzylmethylamine led to the establishment of epithelial cell lines that, after prolonged subculture, produced well-differentiated squamous cell carcinomas following transplantation in vivo.
  • human esophage ⁇ al epithelial cells that are neoplastic have an unlimited ability to replicate in culture, whether neoplastic by virtue of derivation from a cancer or by neoplastic transformation with a tumor virus in culture, such trans ⁇ formed cells are, of course, useless for applications requiring normal cells to detect carcinogenic activities.
  • neoplastic transformation of normal cells into cells that can cause tumors is thought to result from multiple cellular changes.
  • Evidence supporting this concept comes from studies which compared the neoplastic transformation of normal cells and cell lines that were immortalized by genetic transformation with viral and cellular oncogenes. Unlike normal cells, such as those in primary cultures of epithelial cells which are prepared directly from tissues, immortalized cells have the ability to replicate in culture for an indefinite number of generations. The results of the comparative studies indicate that certain oncogenes induce immortalization in normal cells but, by themselves, cannot induce frank neoplasia as evidenced by tumorigenicity.
  • an immortalization gene can cooperate with a second class of oncogene to induce tumorigenic potential.
  • at least some cells that have become immortalized without addition of an exogenous immortalizing oncogene nevertheless require only the second type of oncogene for complete neoplastic transformation into tumor forming cells.
  • a problem with the use of infectious SV40 virus to immortalize cells is that, although the infection with SV40 is not lethal and tends to be self-limiting, the potential for resurgence of more active viral replication persists. Such replication may alter the physiology of the cells and thus render them unreliable for long term culture and chemical testing purposes. Accordingly, the present inventors have been involved in research efforts to extend the replicative potential of various human epithelial cells without introducing genes allowing complete viral synthesis. Within the past year they have demonstrated that genetic transformation with a plasmid containing only certain SV40 genes, namely the so-called early region genes, leads to immortalization of human cells derived from tissues other than esophageal epitheli ⁇ um.
  • epithelial cells from the bronchus include epithelial cells from the bronchus (R.R. Reddel, et al., 1988, Cancer Res., 48:1904-1909; see also U.S. Patent Application Ser. No. 07/114,508 filed October 30, 1987) mesothelium (Y. Ke, et al., 1989, J. Pathol. 134:979-991; see also U.S. Patent Application Ser. No. 07/114,508), and neonatal prostate (M.E. Kaighn, et al., 1989, Cancer Res. 49:3050-3056).
  • pRSV-T The plasmid used to immortalize these cells, which is called pRSV-T, is known in the art (D.E. Brash, R.R. Reddel, M. Quanrad, K. Yang, M.P. Farrell, and C.C. Harris, 1987, Mol. Cell. Biol., 7:2031-2034). It also comprises certain genetic elements from another tumor virus, the Rous sarcoma virus. (Since this plasmid comprises viral genes, the process of genetic transforma- tion in this instance is referred to as "transfection", a term of the art that is a hybrid of the words "transforma ⁇ tion” and "infection".
  • transfection Even though the viral genes of the plasmid are insufficient to produce infectious virus, the use of the term transfection here is convenient for distinguishing the process from that of neoplastic trans ⁇ formation. Accordingly, hereinafter, the term transforma ⁇ tion will be used exclusively in connection with the latter process of neoplasia.
  • transfection procedure using strontium phosphate has yielded stable trans- fectants (i.e., transfected cells) in the several human epithelial cell types cotransfected with the plasmid pRSV- T (as cited above) , and that this strontium procedure is more effective than the traditional calcium phosphate method for insertion of DNA into epithelial cells that are sensitive to high levels of calcium.
  • the present invention contemplates the application of methods of recombinant DNA technology to fulfill the above needs for esophageal cell lines for chemical testing and other purposes. More specifically, it is an object of the present invention to provide a line of human esophage ⁇ al epithelial cells or a derivative thereof having a replicative capacity in cell culture that is enhanced compared to normal cells, and is unable to produce tumors. Further, it is an object of the present invention to provide a cell line of this type which replicates continu ⁇ ously in cell culture.
  • the normal human esophageal epithelial cells can be made to grow continuously by transfecting normal esophageal epithelial cells with the T antigen gene of SV40 virus.
  • the plasmid containing the SV40 early region genes further comprises a genetic element derived from another tumor virus, the long terminal repeat (LTR) or Rous sarcoma virus, which serves to stimulate transcription of the SV40 DNA sequences.
  • LTR long terminal repeat
  • Rous sarcoma virus Rous sarcoma virus
  • Transfection or infection can be accomplished by use of a virus or a plasmid obtaining the T antigen gene of the SV40 virus. Either transfection or infection may lead to transformation of the cell line.
  • Other transfor ⁇ mation vectors may be useful, such as papilloma virus or Epstein Barr virus. Techniques for making continuous human cell lines are described in the following referenc ⁇ es: Grahm, F.L., Smiley J. , Russell, W.C. and Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol., 36: 59-72, 1977; Zur Hausen, H. Oncogenic herpes viruses In: J.
  • the formation of a focus or foci is indicative of carcinogenicity of an agent.
  • a lack of growth of the cell line is indicative of antineoplastic potency of an agent, particularly for esophageal epithelial cells.
  • HE human esophagus
  • NHE normal human esophagus
  • HBS Hepes buffered saline
  • BPE bovine pituitary extract
  • SV40 Simian virus 40
  • CFE colony forming efficiency
  • PD population doublings
  • EM electron microscopy.
  • DESCRIPTION means that the cell line grows continually without senescence when cultured in a suitable growth medium.
  • continuous cell line means that the cell line grows continually without senes ⁇ cence when cultured in a suitable growth medium.
  • the "derivatives" of the esophageal cell line(s) of the present invention include cells which have been further genetically altered by adding, for example, genes for drug metabolizing enzymes, other oncogenes, anti- oxidant genes, or other genes, thereby creating a continu ⁇ ous derivative of the cell line.
  • the present invention relates to a line of human esophageal epithelial cells or a derivative thereof having a replicative capacity in cell culture that is enhanced compared to normal cells and being unable to produce tumors.
  • the general method for obtaining immor ⁇ talized human esophageal epithelial cells is as follows.
  • NHE cells Normal human esophageal (NHE) cells were obtained from explant outgrowths of autopsy specimens from noncan- cerous males. Dispersed cell suspensions were plated at 3-5 x 10 5 cells/dish and transfected with 10 ⁇ g of plasmid pRSV-T coprecipitated with strontium phosphate. After 4 hrs, the cells were shocked with glycerol, as described in Example 1, below. After the appearance of foci of trans ⁇ formed cells, control and transfected cultures were subcultured (2.5 x 10 5 /100-mm dish) . Control strains could be subcultured for no more than 20 PDs, after which they senesced.
  • pRSV-T-transfected cells e.g., lines designated HE-451, HE-457, see below
  • HE-451, HE-457 grew exponentially for approxi- mately 50 PDs, after which they went into crisis.
  • this crisis period which lasted for several months, the majority of cells in both strains senesced. Recovery from this state depended upon their continued maintenance at the highest possible density.
  • two separate immortalized cell lines, designated HET-IA and HET-2A were developed, on each from the HE-451 and HE-457 cultures, respectively.
  • a deposit of the cell lines of the present inven ⁇ tion has been made at the American Type Culture Collec- tion, 12301 Parklawn Drive, Rockville, Maryland, 20852, U.S.A., on August 25, 1989, under accession numbers CRL- 10209 (HET-IA) and CRL-10210 (HET-2A) , in accordance with the Budapest Treaty.
  • the deposits shall be viably main ⁇ tained, replaced if they become non-viable, for a period of 30 years from the date of the deposit, or for 5 years from the last date of request for a sample of the deposit, whichever is longer, and made available to the public without restriction in accordance with the provisions of the law.
  • the Commissioner of Patents and Trademarks, upon request, shall have access to the deposit.
  • the pRSV-T transfected cell lines expressed T- antigen by immunoperoxidase nuclear staining. This is consistent with the Southern blotting data indicating that all lines contain integrated SV40 early region DNA. All transfected lines were confirmed as epithelial by virtue of their positive reaction with antibodies to keratin and the presence of desmosomal junctions and cytoplasmic microfilaments in EM preparations.
  • HET-IA a hypodiploid line
  • HET-IA has a chromosome complement similar to that of pRSV-T immortalized human bronchial epithelial cells (R.R. Reddel, et al., 1988, supra) and prostatic epithelial cells (M.E. Kaighn et al. 1989, supra) .
  • HET-2A cells are larger than those of HET-IA. This is consistent with the observation that the chromosome number of HET-2A cells is in the hypotetraploi ⁇ range whereas HET-IA is hypodiploid.
  • HET-2A cells originated from a male specimen, they had lost the Y chromosome by passage 6. Chromosome analysis indicated that the precursor strain to HET-2A, i.e., HE-451 cells, contain the Y chromosome. Loss of the Y chromosome in transformed cells is frequently observed. In general, instability of the karyotype is a characteris ⁇ tic of virally-transformed cells.
  • UTILITY OF THE CELL LINES Identification of potential carcinogens, tumor promoters and antagonists thereof. These cells are useful for screening chemicals or other agents in the human environment for the potential to neoplastically transform the cells.
  • Putative carcinogens or tumor promoters may be added to the growth medium of the cells and the state of transformation of the cells as a function of time and dose of exposure may be ascertained using anchorage indepen ⁇ dence growth, matrix invasion, cells to cell communication assays, and/or nude mice tumorigenicity assays.
  • Anti- carcinogenic or anti-promoting agents may be added to the medium with carcinogens or promoters and the state of transformation as a function of time may be ascertained as for carcinogens or promoters alone.
  • Such screening could be used to identify specific esophageal toxins in the diet or in other substances and to identify dietary or other compounds that could prevent chemically-induced esophageal cancer. Identification of potential chemotherapeutic drugs. These cells are also useful, either before or after further alteration by other oncogenes or carcino ⁇ gens, for screening chemicals particularly suitable for the treatment of esophageal cancer and related diseases, by growing them in culture medium containing the chemical to be tested and then, after a suitable period of expo ⁇ sure, determining whether and to what extent cytotoxicity has occurred, e.g., by trypan blue exclusion assay or related assays (Paterson, Methods Enzymol., 58:141, 1979), or by growth assays such as colony forming efficiency as described in the examples, herein, all of which are standard techniques well known in the art.
  • Identification of anti-esophageal cancer drugs which act bv inducing terminal cell differentiation Chemical and biological substances are screened for their ability to induce terminal differentiation by adding them to the growth medium of these esophageal cells and then after a suitable period of time, determining whether a complex of changes occurs, including for example, the phenotypic keratin patterns of the normal esophagus (S.P. Banks-Schlegel and C.C. Harris, 1984, Cancer Res. 44:1153- 1157; M.P. Grace, K.H. Kim, L.D. True and E. Fuchs, 1985, Cancer Res. 45:841-846). Induction of terminal differen ⁇ tiation may be an effective way of controlling the growth of cancer.
  • Carcinogens and other xenobiotics may be added to the growth medium of these cells and the appear ⁇ ance of metabolic products of these compounds may be monitored by techniques such as thin layer chromatography or high performance liquid chromatography and the like, and the interaction of the compounds and/or their metabo ⁇ lites with DNA is determined.
  • Studies of DNA mutagenesis Substances known or suspected to be mutagens may be added to the growth medium of the cells and then mutations may be assayed, e.g., by detection of the appearance of drug resistant mutant cell colonies (Thompson, Methods Enzymol., 58:308, 1979).
  • chromosome damaging agents Substances known or suspected to cause DNA or chromosomal damage may be added to the culture medium of these cells lines, and then the extent of chromosomal damage may be measured by techniques such as measurement of the frequency of sister chromatic exchange (Latt et al.. In: Tice, R.R. and Hollander, A., Sister Chromatid Exchanges, New York: Planum Press, pp. 11 ff., 1984), and DNA damage can be determined by the measurement of unscheduled DNA synthesis (Mirsalis, J.C., Banbury Report vol. 13, pp. 83-99, 1982). Studies of malignant transformation bv additional oncogenes.
  • viral agents and genes trans ⁇ ferred by genetic transformation including oncogenes and high molecular weight genomic DNA from tumors, may be tested using standard assays such as anchorage independent growth or tumor formation in athymic nude mice.
  • such cells transformed by an additional oncogene can be used to screen for potential chemotherapeutic agents by the techniques described above, especially those which may be specific for cells transformed by the activation of particular oncogenes or combination of oncogenes.
  • HET-IA cell line Development of the HET-IA cell line.
  • NHE normal human esophageal
  • the outgrowths were suspended with PET [1% polyvi- nylpyrrolidone, 0.02% ethylenebis-(oxyethylenenitrilo) tetraacetic acid, 0.2% crystalline tryspin in HBS, pH 7.4] at room temperature and subcultured into tissue culture dishes or T flasks which had been coated with a mixture of 100 ⁇ g/ml bovine serum albumin, 10 ⁇ g/ml bovine fibro- nectin (both from Calbiochem) , and 20 ⁇ g/ml type 1 colla- gen (Vitrogen 100, Collagen Corp., Palo Alto, CA) to promote cell attachment (J.F. Lechner and M.A. LaVeck, 1985, J. Tissue Culture Meth. 9:43-48).
  • PET 1% polyvi- nylpyrrolidone, 0.02% ethylenebis-(oxyethylenenitrilo) tetraacetic acid, 0.2% crystalline tryspin in HBS, pH 7.4
  • This formulation consisting of modified MCDB 153 supplemented with growth factors (KGM) is available from Clonetics Corporation, San Diego, CA.
  • the basal medium (cKBM) used in these studies and purchased from Clonetics Corporation was a customized modification of KBM without phenol red.
  • other components omitted from cKBM were added just before use CaCl 2 , FeS0 4 , ZnCl 2 , trace element concentrate, thymidine, phospho- ethanolamine, ethanolamine, glutamine and antibiotics) .
  • the growth medium (cKGM-AE consisted of cKBM supplemented with 5 ng/ml epidermal growth factor, 1.4 ⁇ M hydrocortisone, 0.1 mM ethanolamine and phosphoethanol- amine, 5 ⁇ g/ml insulin, 40 ⁇ g/ml bovine pituitary extract (BPE) , 250 ⁇ g/ml bovine serum albumin, and 0.5 ⁇ g/ml epinephrine.
  • Antibiotics were added as needed (100 units/ml penicillin G, 100 ⁇ g/ml kanamycin, 50 ⁇ g/ml gentamicin) .
  • plasmid obtained from Dr. Bruce Howard, NCI, is an ori construct (i.e., lacks the SV40 site for origin of DNA replication) containing the SV40 early region genes and the Rous sarcoma virus long terminal repeat (R.R. Reddel, Y. Ke, B.I. Gerwin, M.G. McMenamin, J.F.
  • strain HE-457 formed two discreet colonies in a single flask. One of these contin ⁇ ued to grow following isolation; the other did not sur- make. At passage 14, this strain (HET-IA) was switched to cKGM-AE medium. Its growth has accelerated, and it has doubled at least 143 times thus far.
  • HET-2A Development of the HET-2A cell line. Based on the observation that the switch to a different growth medium appeared to enhance growth of the few surviving cells of the pRSV-T-transfected cells designated HE-457, a frozen ampoule of the other strain, HE-451, was recovered and cultured in the same medium (cKGM-AE) . In this case, there was a much shorter lag before consistent exponential growth was seen.
  • This line (HET-2A) has now achieved at least 122 PDs.
  • Pre-crisis cultures and immor ⁇ talized cell lines were characterized by immunohistochem- istry. Keratin staining was intensely positive in both pre-crisis strains (HE-451 and HE-457) , especially in closely apposed foci of cells. Vimentin was also posi ⁇ tive, although to a lesser extent than keratin. Numerous atypical nuclear features were observed including dyspla- sia and para-nuclear clearing (koilocytosis) . Keratin stained positively in all cells of both immortalized lines. Both lines stained heterogeneously for vimentin with more intense staining in the smaller cells. Keratin stained much more intensely than vimentin in both cell lines.
  • Chromosome and isozyme analyses Chromosome and isozyme analyses. Chromosome studies were performed by Dr. Ward D. Peterson, Children's Hospital of Michigan, Detroit, MI, using standard methods. Metaphases were stained with Giemsa and counted at low power for ploidy determination. Exact counts on 30 metaphases were made on banded chromosomes, and at least 8 karyotypes per cell line were prepared. Analyses of 8 isozymes were carried out using standard procedures.
  • HET-IA and HET-2A The chromosomal profiles of SV40-T antigen immor ⁇ talized cell lines, HET-IA and HET-2A showed that both lines are aneuploid and each has its own complement of marker chromosomes.
  • HET-IA is hypodiploid with only about 5% of metaphases examined in the hypotetraploid range.
  • Cell line HET-2A is hypotriploid with 28% of metaphases having 100+ chromosomes.
  • DNA was isolated by SDS proteinase-K incuba ⁇ tion followed by phenol/chloroform extraction and ethanol precipitation. The purity of the DNA was assessed spec- trophoto etrically using the 260/280 nm ratio.
  • DNAs (5 ⁇ g each) from cell strains HE-451, HE-457, HOC-517, and HB- 56B, and cell lines RE-149, BEAS-2B, HET-IA and HET-2A were loaded into individual wells of a S&S Slot Blot apparatus (Schleicher and Schuell, Inc., Keene, New Hampshire) . DNA was blotted onto Hybond-N (Amersham) nylon membrane.
  • the samples were probed with a nick- translated EcoRI-Hindlll fragment of the plasmid, pRSV-T in 2x SSC-0.1% SDS at 65°C for 16 hours.
  • the membrane was washed to 0.2x SSC-0.1% SDS at 65°C and autoradiographed at -75°C.
  • a sample (1 ⁇ g) of the plasmid DNA was used as a control.
  • cell strain HOC-517 appears to have incorporated only a few gene copies, longer autoradio- graphic exposures indicated that it is definitely posi ⁇ tive, and that the negative controls, HB-56B and RE149, have no detectable copies of the SV40-T gene.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Cellules épithéliales et oesophagiennes humaines possédant une capacité de réplication dans la culture cellulaire qui est augmentée par rapport aux cellules normales, ces cellules étant incapables de provoquer des tumeurs. Du tissu de l'oesophage humain normal provenant de deux pièces d'autopsie a été explanté dans un milieu dépourvu de sérum. Les excroissances épithéliales ont été repiquées, puis transfectées par la coprécipitation au phosphate des strontium au moyen du pRSV-T plasmidal constitué du promoteur RSV-LTR et du grand gène SV40 de l'antigène-T. Les cellules transfectées ont formé des colonies à plusieurs couches après 3 à 4 semaines, et ont été transférées et développées pour en faire des souches cellulaires (HE-451 et HE-457). Les deux souches ont subi une croissance exponentielle pendant 8 à 10 semaines puis ont subi une sénescence. Après une ''crise'' de 6 à 8 mois, des colonies isolées se sont développées en deux lignées, les HET-1A à partir du HE-457 et HET-2A à partir du HE-451. Les populations de ces lignées ont doublé respectivement 143 et 122 fois. Elles ont toutes les deux une morphologie épithéliale, elles se colorent lors du contact avec la cytokératine et l'antigène-T SV40 au moyen de l'immunofluorescence, et sont restées non tumorgènes dans des souris athymiques pendant 12 mois. Les lignées oesophagiennes immortalisées dans le système dépourvu de sérum sont utiles aux recherches concernant l'action des concérogènes oesophagiens putatifs.
EP19900914817 1989-09-27 1990-09-27 Human esophageal epithelial cell lines Ceased EP0494225A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41280289A 1989-09-27 1989-09-27
US412802 1989-09-27

Publications (2)

Publication Number Publication Date
EP0494225A1 true EP0494225A1 (fr) 1992-07-15
EP0494225A4 EP0494225A4 (en) 1993-04-28

Family

ID=23634550

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900914817 Ceased EP0494225A4 (en) 1989-09-27 1990-09-27 Human esophageal epithelial cell lines

Country Status (5)

Country Link
EP (1) EP0494225A4 (fr)
JP (1) JPH04507046A (fr)
AU (1) AU6449890A (fr)
CA (1) CA2066713A1 (fr)
WO (1) WO1991005062A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585237A (en) * 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
US5658763A (en) * 1993-10-25 1997-08-19 Creative Biomolecules, Inc. Methods and compositions for high protein production from non-native DNA
CA2201216A1 (fr) * 1996-03-29 1997-09-29 Nobuhiro Ibaraki Lignee de cellules epitheliales du cristallin humain

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003994A1 (fr) * 1987-10-30 1989-05-05 The United States Of America, As Represented By Th Lignees cellulaires humaines immortalisees

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003994A1 (fr) * 1987-10-30 1989-05-05 The United States Of America, As Represented By Th Lignees cellulaires humaines immortalisees

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH vol. 45, no. 2, February 1985, PHILADELPHIA pages 841 - 846 GRACE M.P. ET AL 'Keratin expression in normal esophageal epithelium and squamous cell carcinoma of the esophagus' *
IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY vol. 26, no. 3, March 1990, GAITHERSBURG, MD page 23A STONER G.D. ET AL 'Immortalized human esophageal epithelial cell lines for studies of carcinogen-induced cell transformation' *
PROCEEDINGS OF THE EIGHTY-FIRST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH vol. 31, no. 0, March 1990, WASHINGTON page 136 LIGHT, B. ET AL 'Hst-1 induces tumorigenicity in SV40 T antigen immortalized non-tumorigenic, human esophageal epithelial cells' *
See also references of WO9105062A1 *

Also Published As

Publication number Publication date
CA2066713A1 (fr) 1991-03-28
JPH04507046A (ja) 1992-12-10
WO1991005062A1 (fr) 1991-04-18
AU6449890A (en) 1991-04-28
EP0494225A4 (en) 1993-04-28

Similar Documents

Publication Publication Date Title
US4885238A (en) Immortalized human bronchial epitherial mesothelial cell lines
Muruganandam et al. Development of immortalized human cerebromicrovascular endothelial cell line as an in vitro model of the human blood–brain barrier
DE69433822T2 (de) Humane epithelzellinien der leber
US5506131A (en) Immortalized human cell lines containing exogenous cytochrome P450 genes
CA2187099C (fr) Lignees cellulaires prostatiques humaines immortalisees par un virus hybride derive de l'adenovirus 12 et du virus simien 40 (ad12/sv40)
Scholte et al. Immortalization of nasal polyp epithelial cells from cystic fibrosis patients
US6255058B1 (en) Immortalized and malignant human prostatic cell lines
Kulkarnl et al. Characterization of human buccal epithelial cells transfected with the simian virus 40 T-antigen gene
Borek Malignant transformation in vitro: criteria, biological markers, and application in environmental screening of carcinogens
US5443954A (en) Immortalized non-tumorigenic human bronchial epithelial cell lines
EP0494225A1 (fr) Lignees cellulaires epitheliales et oesophagiennes humaines
Wynford-Thomas et al. Conditional immortalization of human thyroid epithelial cells: a tool for analysis of oncogene action
Rhim Multistep carcinogenesis and human epithelial cells
Fusenig et al. Differentiation potential of cancer cells
CA1298220C (fr) Lignees cellulaires humaines immortalisees
US5420033A (en) Epithelial cell line expressing a cystic fibrosis phenotype
EP1172435B1 (fr) Lignées cellulaires de tumeur mammaire de souris exprimant des recepteurs d'estrogène et de progestérone
Armitage Cytogenetic damage, oncogenic transformation and p53 induction in human epithelial cells in response to irradiation
Rhim et al. Techniques for establishing human epithelial cell cultures: Sensitivity of cell lines for propagation of herpesviruses
WO2002048319A1 (fr) Lignees cellulaires humaines de foie immortalisees au moyen de la telomerase
Weng Immortalization and morphological and anchorage-independent transformation of diploid human fibroblasts
HANCOCK Anchorage Independence: Mechanisms of Expression and Relevance to Human Breast Cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920325

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19930603

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19940811